Edwards Lifesciences (NYSE:EW) Updates Q3 2025 Earnings Guidance

Edwards Lifesciences (NYSE:EW - Get Free Report) issued an update on its third quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.540-0.60 for the period, compared to the consensus earnings per share estimate of 0.598. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion. Edwards Lifesciences also updated its FY 2025 guidance to 2.400-2.500 EPS.

Edwards Lifesciences Trading Down 1.6%

EW stock traded down $1.23 during mid-day trading on Thursday, reaching $75.68. 7,464,286 shares of the stock traded hands, compared to its average volume of 4,484,617. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. Edwards Lifesciences has a one year low of $58.93 and a one year high of $78.90. The stock has a market capitalization of $44.39 billion, a PE ratio of 10.81, a PEG ratio of 3.83 and a beta of 1.11. The business has a 50-day moving average price of $76.56 and a two-hundred day moving average price of $73.51.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. Equities research analysts expect that Edwards Lifesciences will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Mizuho upped their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Piper Sandler upped their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Citigroup restated a "buy" rating and issued a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Finally, Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $81.00.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 2,570 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total value of $198,918.00. Following the completion of the transaction, the vice president directly owned 50,356 shares of the company's stock, valued at $3,897,554.40. This trade represents a 4.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the transaction, the insider directly owned 206,900 shares of the company's stock, valued at $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,848 shares of company stock worth $2,314,488 over the last ninety days. 1.29% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

An institutional investor recently bought a new position in Edwards Lifesciences stock. Brighton Jones LLC purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 3,587 shares of the medical research company's stock, valued at approximately $266,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.